{"id":2579,"date":"2025-10-15T14:42:29","date_gmt":"2025-10-15T13:42:29","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=2579"},"modified":"2025-10-15T14:42:29","modified_gmt":"2025-10-15T13:42:29","slug":"lurbinectedin-and-atezolizumab","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/","title":{"rendered":"Lurbinectedin and Atezolizumab in the Treatment of Advanced Small Cell Lung Cancer (ES-SCLC)"},"content":{"rendered":"

Extensive-stage small cell lung cancer (ES-SCLC) remains one of the most challenging types of lung cancer due to its limited response to first-line therapies and high relapse rates. Patients often face difficulties in controlling disease progression after standard treatment regimens combining chemotherapy and immunotherapy.<\/p>\n

On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved the combination of Lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.)<\/strong> and Atezolizumab (Tecentriq, Genentech Inc.)<\/strong>, as well as Atezolizumab plus Hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.)<\/strong>, as maintenance therapy for adults with ES-SCLC who have not experienced disease progression after first-line treatment with Atezolizumab (or Atezolizumab plus Hyaluronidase-tqjs) in combination with carboplatin and etoposide (FDA, 2025). This approval was supported by results from the IMforte trial (NCT05091567)<\/strong>, which demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS).<\/p>\n

 <\/p>\n

Table of Contents<\/strong><\/p>\n

    \n
  1. Introduction to Lurbinectedin and Atezolizumab<\/a><\/li>\n
  2. Overview of the IMforte Clinical Trial<\/a><\/li>\n
  3. Recommended Doses and Administration<\/a><\/li>\n
  4. Safety Warnings and Precautions<\/a><\/li>\n
  5. FDA Expedited Programs and Project Orbis<\/a><\/li>\n
  6. Conclusion and Clinical Outlook<\/a><\/li>\n
  7. Frequently Asked Questions (FAQs)<\/a><\/li>\n<\/ol>\n

    1. Introduction to Lurbinectedin and Atezolizumab<\/h2>\n

    1.1 Mechanism of Action of Lurbinectedin<\/strong><\/p>\n

    Lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) is a novel anticancer agent designed to inhibit cancer cell proliferation and induce apoptosis, thereby controlling tumor growth. It is indicated as maintenance therapy in ES-SCLC patients after completion of first-line treatment (FDA, 2025).<\/p>\n

    1.2 Mechanism of Action of Atezolizumab and Hyaluronidase-tqjs<\/strong><\/p>\n

    Atezolizumab (Tecentriq, Genentech Inc.) is a monoclonal antibody targeting the PD-L1 pathway, enabling the immune system to recognize and destroy cancer cells. When combined with Hyaluronidase-tqjs (Tecentriq Hybreza), drug penetration into tumor tissues is enhanced, increasing treatment efficacy (FDA, 2025).<\/p>\n

    1.3 Benefits of the Combination Therapy<\/strong><\/p>\n

    Clinical studies have shown that the combination of Lurbinectedin and Atezolizumab significantly improves both OS and PFS compared to Atezolizumab monotherapy (ClinicalTrials.gov, NCT05091567).<\/p>\n

    2. Overview of the IMforte Clinical Trial<\/h2>\n

    2.1 Study Design<\/strong><\/p>\n

    The IMforte trial was a randomized, multicenter, open-label study involving 483 ES-SCLC patients. Eligible participants had not shown disease progression after four cycles of first-line therapy with Atezolizumab, Carboplatin, and Etoposide. Patients were randomized into two groups:<\/p>\n

      \n
    1. Lurbinectedin plus Atezolizumab<\/li>\n
    2. Atezolizumab alone (ClinicalTrials.gov, NCT05091567)<\/li>\n<\/ol>\n

      2.2 Key Results (OS and PFS)<\/strong><\/p>\n

        \n
      • Overall Survival (OS):<\/strong> Median 13.2 months in the combination group vs. 10.6 months in the control group (HR = 0.73; p = 0.0174)<\/li>\n
      • Progression-Free Survival (PFS):<\/strong> Median 5.4 months in the combination group vs. 2.1 months in the control group (HR = 0.54; p < 0.0001) (FDA, 2025)<\/li>\n<\/ul>\n

        These findings indicate that the combination therapy significantly prolongs both survival outcomes compared to monotherapy.<\/p>\n

        2.3 Data Analysis<\/strong><\/p>\n

        The IMforte trial results confirm that the Lurbinectedin\u2013Atezolizumab regimen provides measurable clinical benefits in ES-SCLC patients. All interpretations are strictly based on published trial data (ClinicalTrials.gov, NCT05091567).<\/p>\n

        3. Recommended Doses and Administration<\/h2>\n
          \n
        • Lurbinectedin:<\/strong> 3.2 mg\/m\u00b2 intravenously every 21 days<\/li>\n
        • Atezolizumab:<\/strong> 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks intravenously<\/li>\n
        • Atezolizumab + Hyaluronidase-tqjs:<\/strong> 1875 mg Atezolizumab plus 30,000 units Hyaluronidase subcutaneously every 3 weeks (FDA, 2025)<\/li>\n<\/ul>\n

          4. Safety Warnings and Precautions<\/h2>\n
            \n
          • Lurbinectedin:<\/strong> Myelosuppression, hepatotoxicity, tissue necrosis from extravasation, rhabdomyolysis, and embryo-fetal toxicity<\/li>\n
          • Atezolizumab \u00b1 Hyaluronidase-tqjs:<\/strong> Severe immune-related adverse events, infusion-related reactions, complications in allogeneic stem cell transplant, embryo-fetal toxicity<\/li>\n
          • Safety Reporting:<\/strong> Serious adverse events must be reported via the FDA MedWatch system (FDA, 2025)<\/li>\n<\/ul>\n

            5. FDA Expedited Programs and Project Orbis<\/h2>\n
              \n
            • Reviewed under Project Orbis<\/strong>, enabling concurrent international evaluation in Australia, Canada, Israel, and Switzerland<\/li>\n
            • Granted Priority Review<\/strong> and Orphan Drug Designation<\/strong> to accelerate regulatory approval<\/li>\n
            • Provides a legal and clinical framework for future oncology research and combination therapies (FDA, 2025)<\/li>\n<\/ul>\n

              6. Conclusion and Clinical Outlook<\/strong><\/p>\n

              The FDA approval of Lurbinectedin in combination with Atezolizumab represents a milestone in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Supported by the IMforte trial, this regimen demonstrated significant improvements in overall survival and progression-free survival compared to standard immunotherapy alone. These findings establish the combination as a validated, evidence-based option for maintenance therapy in adult ES-SCLC patients and highlight a new direction in the clinical management of this aggressive cancer.<\/p>\n

              7. Frequently Asked Questions (FAQs)<\/strong><\/p>\n

                \n
              • For which condition was Lurbinectedin approved?
                \n<\/strong>It was approved as maintenance therapy for adult patients with ES-SCLC (FDA, 2025).<\/li>\n
              • What are the main benefits of the Lurbinectedin and Atezolizumab combination?
                \n<\/strong>It significantly improves overall survival (OS) and progression-free survival (PFS) compared to Atezolizumab monotherapy (ClinicalTrials.gov, NCT05091567).<\/li>\n
              • What are the main side effects patients should be aware of?
                \n<\/strong>Myelosuppression, severe immune-related events, hepatotoxicity, and tissue necrosis (FDA, 2025).<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

                Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment<\/p>\n","protected":false},"author":2,"featured_media":2582,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[120],"tags":[],"class_list":["post-2579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-medicine"],"acf":[],"yoast_head":"\nLurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment<\/title>\n<meta name=\"description\" content=\"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Lenus Health\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T13:42:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"873\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"login-hashemzadeh-dash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"login-hashemzadeh-dash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\"},\"author\":{\"name\":\"login-hashemzadeh-dash\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09\"},\"headline\":\"Lurbinectedin and Atezolizumab in the Treatment of Advanced Small Cell Lung Cancer (ES-SCLC)\",\"datePublished\":\"2025-10-15T13:42:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\"},\"wordCount\":712,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg\",\"articleSection\":[\"New medicines\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\",\"url\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\",\"name\":\"Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment\",\"isPartOf\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg\",\"datePublished\":\"2025-10-15T13:42:29+00:00\",\"description\":\"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).\",\"breadcrumb\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage\",\"url\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg\",\"contentUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg\",\"width\":1600,\"height\":873},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lenus-healthcare.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New medicines\",\"item\":\"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Lurbinectedin and Atezolizumab in the Treatment of Advanced Small Cell Lung Cancer (ES-SCLC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lenus-healthcare.com\/#website\",\"url\":\"https:\/\/lenus-healthcare.com\/\",\"name\":\"Lenus Health\",\"description\":\"Lenus Health Gmbh | Berlin\",\"publisher\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lenus-healthcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\",\"name\":\"Lenus Health\",\"url\":\"https:\/\/lenus-healthcare.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp\",\"contentUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp\",\"width\":1275,\"height\":298,\"caption\":\"Lenus Health\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09\",\"name\":\"login-hashemzadeh-dash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"caption\":\"login-hashemzadeh-dash\"},\"url\":\"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment","description":"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/","og_locale":"en_US","og_type":"article","og_title":"Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment","og_description":"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).","og_url":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/","og_site_name":"Lenus Health","article_published_time":"2025-10-15T13:42:29+00:00","og_image":[{"width":1600,"height":873,"url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg","type":"image\/jpeg"}],"author":"login-hashemzadeh-dash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"login-hashemzadeh-dash","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#article","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/"},"author":{"name":"login-hashemzadeh-dash","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09"},"headline":"Lurbinectedin and Atezolizumab in the Treatment of Advanced Small Cell Lung Cancer (ES-SCLC)","datePublished":"2025-10-15T13:42:29+00:00","mainEntityOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/"},"wordCount":712,"commentCount":0,"publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg","articleSection":["New medicines"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/","url":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/","name":"Lurbinectedin and Atezolizumab in Advanced ES-SCLC Treatment","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg","datePublished":"2025-10-15T13:42:29+00:00","description":"FDA approved Lurbinectedin plus Atezolizumab as maintenance therapy for advanced small cell lung cancer (ES-SCLC).","breadcrumb":{"@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#primaryimage","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/Small-Cell-Lung-CancerTH.jpg","width":1600,"height":873},{"@type":"BreadcrumbList","@id":"https:\/\/lenus-healthcare.com\/en\/lurbinectedin-and-atezolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lenus-healthcare.com\/en\/"},{"@type":"ListItem","position":2,"name":"New medicines","item":"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/"},{"@type":"ListItem","position":3,"name":"Lurbinectedin and Atezolizumab in the Treatment of Advanced Small Cell Lung Cancer (ES-SCLC)"}]},{"@type":"WebSite","@id":"https:\/\/lenus-healthcare.com\/#website","url":"https:\/\/lenus-healthcare.com\/","name":"Lenus Health","description":"Lenus Health Gmbh | Berlin","publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lenus-healthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lenus-healthcare.com\/#organization","name":"Lenus Health","url":"https:\/\/lenus-healthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","width":1275,"height":298,"caption":"Lenus Health"},"image":{"@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09","name":"login-hashemzadeh-dash","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","caption":"login-hashemzadeh-dash"},"url":"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/"}]}},"_links":{"self":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/comments?post=2579"}],"version-history":[{"count":3,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2579\/revisions"}],"predecessor-version":[{"id":2584,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2579\/revisions\/2584"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media\/2582"}],"wp:attachment":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media?parent=2579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/categories?post=2579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/tags?post=2579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}